Breakout Session III
Decentralised Trials: Making The Model Work
Cross-border and decentralised trials represent one of the most significant shifts in how clinical research is conducted — but turning the model into standard practice requires more than enthusiasm. This session examines the full picture of what successful execution actually looks like, how sites and sponsors have navigated e-consenting, logistics, and regulatory complexity, and what existing programs have learned along the way. Evaluate what it takes to build decentralized capabilities at the site level with tools to assess your site’s readiness.
From Feasibility To First Choice: What Sponsors Really Want
Many sites — particularly newer, smaller, or primary care-based sites — struggle to get noticed by sponsors during feasibility and site selection. Hear how selection decisions are made, what sponsors and CROs are actually evaluating, and what both sides can do differently. Learn how sites can improve their positioning in feasibility questionnaires, how data-driven selection models are changing the landscape, and how sites can transition from study-by-study delivery to strategic long-term partnership.
How Site Performance Is Evaluated
Recruitment performance data is routinely used to make site selection, continuation, and reputation decisions — but the metrics rarely account for the factors that most affect them. Sites activated late in a study, those that faced delayed IMP delivery, those that had a single week of recruitment window: all are measured against the same benchmarks. This session considers how sponsors, CROs, and sites can adopt more contextual, fair approaches to evaluating site and country performance. Explore what a better KPI framework looks like, how to make the case for it, and what data sites should be tracking to protect themselves in performance conversations.
How Site Performance Is Evaluated
Recruitment performance data is routinely used to make site selection, continuation, and reputation decisions — but the metrics rarely account for the factors that most affect them. Sites activated late in a study, those that faced delayed IMP delivery, those that had a single week of recruitment window: all are measured against the same benchmarks. This session considers how sponsors, CROs, and sites can adopt more contextual, fair approaches to evaluating site and country performance. Explore what a better KPI framework looks like, how to make the case for it, and what data sites should be tracking to protect themselves in performance conversations.
Investment Strategy For Site Technology
Sites making smart, strategic technology investments are seeing real financial returns — and their lessons are worth learning from. Site leaders will share what’s delivering measurable ROI, how to build a winning investment case, and the frameworks that separate high-value tools from costly distractions.
Supporting Investigators Of Tomorrow
Behind every successful clinical trial is an engaged, accountable Principal Investigator — yet investigator burnout, competing clinical responsibilities, expanding regulatory expectations, and thin succession pipelines are threatening site sustainability. We’ll review the evolving PI role head-on, sharing what oversight means in practice, how sites are balancing clinical care with research commitments, what recognition and compensation models are working, and building succession plans that will support the next generation of site leaders.
Where To Grow Next: Therapeutic Area Opportunities
Not every therapeutic area is the right fit for every site — and the sites that grow successfully make deliberate, informed choices about where to compete. We’ll explore how to evaluate your site’s current portfolio, identify adjacent opportunities worth pursuing, and build the capabilities needed to move into new areas with confidence. From pipeline analysis, sponsor demand signals, team development and risk assessment, you’ll walk away with a sharper sense of where your site is best positioned to grow.